Tecemotide, Merck KGaA's 9-lived cancer vaccine, has flunked another clinical trial, missing its main goal in a Japanese study and casting further doubts on the program's future.
Shares of Oncothyreon soared this morning after its partner Merck KGaA said it would take a second swipe at trying to find some value in Stimuvax, the cancer vaccine (now renamed tecemotide) that has already decisively flunked a Phase III trial.
Despite flunking a Phase III trial in December, Merck KGaA is still talking about its lung cancer vaccine. The company has decided to push on with another ongoing late-phase trial in Asia and is now weighing the options of starting a further study.
After taking its big Phase III study of Stimuvax all the way to a conclusive finish, Merck KGaA said the closely-watched lung cancer vaccine failed to demonstrate a significant improvement in overall survival--a flop that will leave a deep scar at Oncothyreon as well, which licensed out the treatment.
Cancer vaccines are becoming an increasingly attractive focus of study, but there are still perils and pitfalls along the way to success. Two recent studies have looked at ways to get around these, focusing on experimental cancer vaccines boosted by existing drugs.
Oncothyreon ($ONTY), which takes its name from the Greek words for 'tumor' and 'shield', has enrolled the first patient into its inaugural ONT-10 clinical trial.
Merck KGaA told analysts today that after assessing its late-stage study for the lung cancer vaccine Stimuvax in a second interim analysis, investigators were told to push on to an ultimate read-out...
Merck KGaA and Oncothyreon ($ONTY) will learn soon whether their lung cancer vaccine has a shot at being one of the next bright lights in the cancer immunotherapy arena, with an interim analysis set
Oncothyreon ($ONTY) execs are expecting interim results from a late-stage study of lung cancer vaccine Stimuvax sometime this quarter. Results from the 1,514-person trial, which is being conducted by...
Now that Provenge and Yervoy have been approved, specialists are keying in on a new generation of immunotherapies that promise to change the standard of care for cancer. As Stephen Hodi, director of